Abstract：
Cancer patients suffer from complicated chemotoxicity. Pharmacogenomics can help stratify patients by predicting their response to treatment and susceptibility toward severe side effects. The spindle-assembly checkpoint (SAC) is an important pathway that is activated by platinum and taxane compounds and plays a crucial role in their cytotoxic activity. This study investigated a SAC component, Budding Uninhibited by Benzimidazoles 3 (BUB3), its expression, and genetic variants in advanced ovarian cancer patients treated with paclitaxel-carboplatin chemotherapy. Among 80 patients, BUB3 expression correlated with chemosensitivity, suggesting its potential as a predictive marker for chemotherapy response. However, high BUB3 expression was associated with a higher risk of poor survival. In addition, genetic polymorphisms in BUB3 (rs11248416 and rs11248419) were significantly linked to chemotherapy-related toxicities, with rs11248416 showing a negative impact on the patient\'s physical quality of life.
摘要：
癌症患者患有复杂的化学毒性。药物基因组学可以通过预测患者对治疗的反应和对严重副作用的易感性来帮助患者分层。纺锤体组装检查点（SAC）是铂和紫杉烷化合物激活的重要途径，在其细胞毒性活性中起着至关重要的作用。这项研究调查了SAC组件，不受苯并咪唑3（BUB3）抑制的出芽，它的表达，紫杉醇-卡铂化疗治疗的晚期卵巢癌患者的遗传变异。在80名患者中，BUB3表达与化疗敏感性相关，提示其作为化疗反应的预测指标的潜力。然而,高BUB3表达与较高生存率相关.此外,BUB3的遗传多态性（rs11248416和rs11248419）与化疗相关的毒性显著相关，rs11248416对患者的身体生活质量有负面影响。
